DeepMed Research

Cilofexor

Generic Name: Cilofexor

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₂₂Cl_₃N_₃O_₅

CAS Number: 1418274-28-8

Unique Ingredient Identifier: YUN2306954

Background: Cilofexor is under investigation in clinical trial NCT02943447 (Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis).

Clinical Trials

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Phase 2

Completed

Conditions: Nonalcoholic Steatohepatitis

Interventions: Drug: PTM SEMA
Drug: Semaglutide (SEMA)
Drug: Cilofexor (CILO)/Firsocostat (FIR)
Drug: PTM CILO/FIR

First Posted Date: 2021-07-21

Last Posted Date: 2025-01-08

Lead Sponsor: Gilead Sciences

Target Recruit Count: 457

Registration Number: NCT04971785

Locations: 🇺🇸
Charter Research, Winter Park, Florida, United States
🇺🇸
Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸
Rush University Medical Group - Department of Hepatology, Chicago, Illinois, United States

and more 226 locations

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

Phase 1

Terminated

Conditions: Compensated Cirrhosis
Primary Sclerosing Cholangitis

Interventions: Drug: Cilofexor

First Posted Date: 2019-08-16

Last Posted Date: 2023-07-27

Lead Sponsor: Gilead Sciences

Target Recruit Count: 11

Registration Number: NCT04060147

Locations: 🇺🇸
Arizona Liver Health, Chandler, Arizona, United States
🇺🇸
California Liver Research Institute, Pasadena, California, United States
🇺🇸
University of California San Francisco, Liver Clinic, San Francisco, California, United States

and more 13 locations

Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

Phase 2

Completed

Conditions: Nonalcoholic Steatohepatitis

Interventions: Drug: Semaglutide
Drug: Firsocostat
Drug: Cilofexor

First Posted Date: 2019-06-14

Last Posted Date: 2021-07-15

Lead Sponsor: Gilead Sciences

Target Recruit Count: 109

Registration Number: NCT03987074

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Institute for Liver Health - Arizona Liver Health, Chandler, Arizona, United States
🇺🇸
Quality Medical Research, PLLC, Nashville, Tennessee, United States

and more 14 locations

Study of Cilofexor in Adults With Primary Sclerosing Cholangitis

Phase 3

Terminated

Conditions: Primary Sclerosing Cholangitis

Interventions: Drug: Cilofexor
Drug: Placebo

First Posted Date: 2019-03-26

Last Posted Date: 2023-11-29

Lead Sponsor: Gilead Sciences

Target Recruit Count: 419

Registration Number: NCT03890120

Locations: 🇺🇸
Texas Clinical Research Institute, Arlington, Texas, United States
🇺🇸
Ruane Clinical Research Group Inc., Los Angeles, California, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 198 locations

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis

Phase 2

Terminated

Conditions: Primary Biliary Cholangitis

Interventions: Drug: Cilofexor
Drug: Placebo to match cilofexor

First Posted Date: 2016-10-24

Last Posted Date: 2020-09-22

Lead Sponsor: Gilead Sciences

Target Recruit Count: 71

Registration Number: NCT02943447

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

Phase 2

Completed

Conditions: Primary Sclerosing Cholangitis

Interventions: Drug: Cilofexor
Drug: Placebo to match cilofexor

First Posted Date: 2016-10-24

Last Posted Date: 2021-06-07

Lead Sponsor: Gilead Sciences

Target Recruit Count: 52

Registration Number: NCT02943460

Locations: 🇺🇸
The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States
🇦🇹
Universitätsklinik Klinik für Innere Medizin III, Vienna, Austria
🇨🇦
University of Calgary Liver Unit (Heritage Medical Research Clinic), Calgary, Alberta, Canada

and more 20 locations

Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

Phase 2

Completed

Conditions: Nonalcoholic Steatohepatitis (NASH)

Interventions: Drug: GS-9674
Drug: Placebo to match GS-9674

First Posted Date: 2016-08-03

Last Posted Date: 2019-01-29

Lead Sponsor: Gilead Sciences

Target Recruit Count: 140

Registration Number: NCT02854605

Locations: 🇨🇦
Toronto Liver Center, Toronto, Ontario, Canada
🇨🇦
LMC Clinical Research Inc (Bayview), Toronto, Ontario, Canada
🇺🇸
Clinical Research of South Florida, Coral Gables, Florida, United States

and more 34 locations

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

Phase 1

Completed

Conditions: Nonalcoholic Steatohepatitis (NASH)
Primary Sclerosing Cholangitis (PSC)

Interventions: Drug: Cilofexor

First Posted Date: 2016-06-21

Last Posted Date: 2021-01-07

Lead Sponsor: Gilead Sciences

Target Recruit Count: 57

Registration Number: NCT02808312

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

Phase 1

Completed

Conditions: Nonalcoholic Steatohepatitis (NASH)

Interventions: Drug: Cilofexor
Drug: Placebo

First Posted Date: 2016-01-13

Last Posted Date: 2020-10-12

Lead Sponsor: Gilead Sciences

Target Recruit Count: 120

Registration Number: NCT02654002

Locations: 🇺🇸
SeaView Research, Inc, Miami, Florida, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy